Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 3/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.65 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.65 |
| ▸ | SHBG | P04278 | 3/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | MGAM | O43451 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9541973 | 1.00 | AKR1B10 (0.65) | AKR1B10AKR1B1CYP19A1OR51E2SHBG | |
| SCHEMBL27607786 | 1.00 | AKR1B10 (0.65) | AKR1B10AKR1B1CYP19A1OR51E2SHBG | |
| SCHEMBL4572602 | 1.00 | AKR1B10 (0.65) | AKR1B10AKR1B1CYP19A1OR51E2SHBG | |
| SCHEMBL27248784 | 1.00 | AKR1B10 (0.65) | AKR1B10AKR1B1CYP19A1OR51E2SHBG | |
| SCHEMBL1651202 | 1.00 | AKR1B10 (0.65) | AKR1B10AKR1B1CYP19A1OR51E2SHBG | |
| SCHEMBL24151978 | 1.00 | AKR1B10 (0.65) | AKR1B10AKR1B1CYP19A1OR51E2SHBG | |
| SCHEMBL19877200 | 1.00 | AKR1B10 (0.65) | AKR1B10AKR1B1CYP19A1OR51E2SHBG | |
| SCHEMBL1962644 | 1.00 | AKR1B10 (0.65) | AKR1B10AKR1B1CYP19A1OR51E2SHBG | |
| Propionic Acid SCHEMBL12694801 | 0.91 | GPBAR1 (0.57) | AKR1B10AKR1B1CYP19A1OR51E2SHBG | |
| Stanolone SCHEMBL11325499 | 0.91 | SHBG (0.82) | AKR1B10AKR1B1CYP19A1OR51E2SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112370528-A | Pheromone composition with marking function and preparation thereof | 宁波三生生物科技有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-110604754-A | Pheromone composition capable of improving estrus mating rate of sows | 宁波第二激素厂 | 2019-12-24 | — | — | CN | claimed |
| EP-2938654-B1 | MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | OREAL (FR) | 2016-08-24 | — | — | EP | claimed |
| US-20150342868-A1 | MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | LOREAL (FR) | 2015-12-03 | — | — | US | claimed |
| US-20150320667-A1 | MOLECULARLY IMPRINTED POLYMER FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | L'OREAL (FR) | 2015-11-12 | — | — | US | claimed |
| EP-2938654-A1 | MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | L'OREAL (FR) | 2015-11-04 | — | — | EP | claimed |
| EP-2160190-B1 | 5BETA, 14BETA-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES DUE TO ORGAN FIBROSIS | SIGMA TAU IND FARMACEUTI (IT) | 2015-11-04 | — | — | EP | claimed |
| EP-2938402-A1 | MOLECULARLY IMPRINTED POLYMER FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | L'OREAL (FR) | 2015-11-04 | — | — | EP | claimed |
| WO-2014102077-A1 | MOLECULARLY IMPRINTED POLYMER FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | L'OREAL (FR) | 2014-07-03 | — | — | WO | claimed |
| WO-2014102078-A1 | MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | L'OREAL (FR) | 2014-07-03 | — | — | WO | claimed |
| EP-2160190-A1 | 5BETA, 14BETA-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF RESTENOSIS AFTER ANGIOPLASTIC OR ENDOARTHERECTOMY AND DISEASES DUE TO ORGAN FIBROSIS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2010-03-10 | — | — | EP | claimed |
| WO-2008148812-A1 | 5BETA, 14BETA-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF RESTENOSIS AFTER ANGIOPLASTIC OR ENDOARTHERECTOMY AND DISEASES DUE TO ORGAN FIBROSIS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-12-11 | — | — | WO | claimed |
| WO-1998024451-A1 | USES OF OXANDROLONE | BIO-TECHNOLOGY GENERAL CORP. (US) | 1998-06-11 | — | — | WO | claimed |
| WO-1998024449-A1 | THE USE OF OXANDROLONE IN THE TREATMENT OF A NEUROLOGICAL DISORDER | FENICHEL GERALD (US) | 1998-06-11 | — | — | WO | claimed |
| EP-0649431-A4 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5-G(A)-REDUCTASE INHIBITORS. | — | 1995-05-03 | — | — | EP | claimed |
| EP-0649431-A1 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5$g(a)-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1995-04-26 | — | — | EP | claimed |
| EP-0558509-B1 | USE OF MEDICAGO SAPONINS FOR THE PREPARATION OF COSMETIC OR PHARMACEUTICAL COMPOSITIONS, DERMATOLOGICAL COMPOSITIONS IN PARTICULAR, HELPING RENEW THE EPIDERMIS, STIMULATING REGROWTH OF HAIR, OR DELAYING HAIR LOSS | LVMH RECH (FR) | 1995-03-15 | — | — | EP | claimed |
| WO-1993023038-A1 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| EP-4728019-A1 | A MICROWAVE CARBONIZATION ASSEMBLY AND METHOD FOR EXTRACTING COMPONENTS FROM RUBBER | Sable Rubber IP Pty Limited (AU) | 2026-04-22 | — | — | EP | disclosed |
| US-4013688-A | STEROIDS | THE UPJOHN COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342868-A1 | MOLECULARLY IMPRINTED POLYMER OF SOL-GEL TYPE FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | TAS2R30, TAS1R1, TAS2R10 | AKR1B10 1374/4885AKR1B1 1973/4885CYP19A1 1246/4885 |
| US-20150320667-A1 | MOLECULARLY IMPRINTED POLYMER FOR SELECTIVELY TRAPPING ODOROUS MOLECULES | OR10J3, OR51E2, MSMO1 | AKR1B10 1115/4885AKR1B1 1386/4885CYP19A1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.